New and Emerging Therapies for Metastatic Melanoma

Publication
Article
Special ReportsMelanoma (Issue 2)
Volume 2
Issue 1

Ryan J. Sullivan, MD, medical oncologist, Massachusetts General Hospital, gives an overview of new and emerging therapies for the treatment of metastatic melanoma.

Ryan J. Sullivan, MD, medical oncologist, Massachusetts General Hospital, gives an overview of new and emerging therapies for the treatment of metastatic melanoma.

Read more about the treatment of metastatic melanoma > >

Articles in this issue
Sequencing Strategies in Treating Patients With Melanoma
Sequencing Strategies in Treating Patients With Melanoma
Research Into Newer Agents Under Way for NRAS Melanoma
Research Into Newer Agents Under Way for NRAS Melanoma
New Crop of Combination Strategies Growing for Melanoma
New Crop of Combination Strategies Growing for Melanoma
An Overview of Immune Checkpoint Blockade
An Overview of Immune Checkpoint Blockade
Approaches to Sequencing in Melanoma: Three Melanoma Specialists Weigh In
Approaches to Sequencing in Melanoma: Three Melanoma Specialists Weigh In
In Practice: Combination Therapies in Metastatic Melanoma
In Practice: Combination Therapies in Metastatic Melanoma
New and Emerging Therapies for Metastatic Melanoma
New and Emerging Therapies for Metastatic Melanoma
Mutation Tests in Melanoma Crucial for Treatment
Mutation Tests in Melanoma Crucial for Treatment
What’s Next With Next-Generation BRAF Inhibitors?
What’s Next With Next-Generation BRAF Inhibitors?
Related Videos
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on melanoma
Michael B. Atkins, MD, an expert on skin cancer
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Related Content
Lenvatinib Is Effective, Regardless of Age in HCC

Lenvatinib Is Effective, Regardless of Age in HCC

April 23rd 2024
Article

No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.

Read More

Navigating the Landscape of Immunotherapy Toxicities

Navigating the Landscape of Immunotherapy Toxicities

November 30th 2023
Podcast

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

Listen

April Roundtable Roundup: B-cell Lymphoma

April Roundtable Roundup: B-cell Lymphoma

April 22nd 2024
Article

In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.

Read More

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

June 30th 2023
Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen

Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer

Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer

April 20th 2024
Article

During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.

Read More

To Detect More Alterations, Consider Adding Companion Testing to NGS

To Detect More Alterations, Consider Adding Companion Testing to NGS

April 19th 2024
Article

Druggable gene aberrations and predictive biomarkers has allowed for the use of next-generation sequencing technologies to grow.

Read More